NPJ Vaccines最新文献_第8页

CRISPR/Cas9 screens identify key host factors that enhance rotavirus reverse genetics efficacy and vaccine production. CRISPR/Cas9 筛选确定了可提高轮状病毒反向遗传效力和疫苗生产的关键宿主因子。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2024-11-06 DOI: 10.1038/s41541-024-01007-7

Yinxing Zhu, Meagan E Sullender, Danielle E Campbell, Leran Wang, Sanghyun Lee, Takahiro Kawagishi, Gaopeng Hou, Alen Dizdarevic, Philippe H Jais, Megan T Baldridge, Siyuan Ding

{"title":"CRISPR/Cas9 screens identify key host factors that enhance rotavirus reverse genetics efficacy and vaccine production.","authors":"Yinxing Zhu, Meagan E Sullender, Danielle E Campbell, Leran Wang, Sanghyun Lee, Takahiro Kawagishi, Gaopeng Hou, Alen Dizdarevic, Philippe H Jais, Megan T Baldridge, Siyuan Ding","doi":"10.1038/s41541-024-01007-7","DOIUrl":"10.1038/s41541-024-01007-7","url":null,"abstract":"Rotaviruses pose a significant threat to young children. To identify novel pro- and anti-rotavirus host factors, we performed genome-wide CRISPR/Cas9 screens using rhesus rotavirus and African green monkey cells. Genetic deletion of either SERPINB1 or TMEM236, the top two antiviral factors, in MA104 cells increased virus titers in a rotavirus strain independent manner. Using this information, we optimized the existing rotavirus reverse genetics systems by combining SERPINB1 knockout MA104 cells with a C3P3-G3 helper plasmid. We improved the recovery efficiency and rescued several low-titer rotavirus reporter and mutant strains that prove difficult to rescue otherwise. Furthermore, we demonstrate that TMEM236 knockout in Vero cells supported higher yields of two live-attenuated rotavirus vaccine strains than the parental cell line and represents a more robust vaccine-producing cell substrate. Collectively, we developed a third-generation optimized rotavirus reverse genetics system and generated gene-edited Vero cells as a new substrate for improving rotavirus vaccine production.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"9 1","pages":"211"},"PeriodicalIF":6.9,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11542071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Leishmania tarentolae as a platform for the production of vaccines against viral pathogens. 以利什曼原虫为平台生产抗病毒病原体疫苗。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2024-11-06 DOI: 10.1038/s41541-024-01005-9

Marta Zimna, Ewelina Krol

引用次数: 0

Safety, efficacy and immunogenicity of aerosolized Ad5-nCoV COVID-19 vaccine in a non-inferiority randomized controlled trial. 气雾化 Ad5-nCoV COVID-19 疫苗在非劣效性随机对照试验中的安全性、有效性和免疫原性。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2024-10-31 DOI: 10.1038/s41541-024-01003-x

Chun K Chew, Ruijie Wang, Sunita Bavanandan, Norliza Zainudin, Xiaoyuan Zhao, Sumeyya Ahmed, Damenthi Nair, Lihua Hou, Rosnawati Yahya, Shereen S Ch'ng, Lai H Pang, Azrini Abdul Aziz, Haitao Huang, Reena Rajasuriar, Shipo Wu, Zhe Zhang, Xuewen Wang, Geok Y Chun, Aisyah Mohd Norzi, Kit Y Cheah, Yi L Lee, Wan H Wan Mohamad, Mohamad R Mohd Din, Wan M R Wan Ahmad Kamil, Min H Tan, Xiaoyu Xu, Lina Wang, Meixu Yan, Yusi Liu, Voon K Chin, Jau S Teo, Teck O Lim, Tao Zhu, Jinbo Gou, Sharon S M Ng

{"title":"Safety, efficacy and immunogenicity of aerosolized Ad5-nCoV COVID-19 vaccine in a non-inferiority randomized controlled trial.","authors":"Chun K Chew, Ruijie Wang, Sunita Bavanandan, Norliza Zainudin, Xiaoyuan Zhao, Sumeyya Ahmed, Damenthi Nair, Lihua Hou, Rosnawati Yahya, Shereen S Ch'ng, Lai H Pang, Azrini Abdul Aziz, Haitao Huang, Reena Rajasuriar, Shipo Wu, Zhe Zhang, Xuewen Wang, Geok Y Chun, Aisyah Mohd Norzi, Kit Y Cheah, Yi L Lee, Wan H Wan Mohamad, Mohamad R Mohd Din, Wan M R Wan Ahmad Kamil, Min H Tan, Xiaoyu Xu, Lina Wang, Meixu Yan, Yusi Liu, Voon K Chin, Jau S Teo, Teck O Lim, Tao Zhu, Jinbo Gou, Sharon S M Ng","doi":"10.1038/s41541-024-01003-x","DOIUrl":"10.1038/s41541-024-01003-x","url":null,"abstract":"This phase 3, observer-blinded, non-inferiority randomized trial (ClinicalTrials.gov: NCT05517642), conducted from September 2022 to May 2023 at three Malaysian sites, involved 540 adults previously vaccinated with three COVID-19 doses. Participants were randomized 1:1 to receive either one dose of inhaled Recombinant COVID-19 Vaccine (Ad5-nCoV-IH) or intramuscular tozinameran (BNT-IM). The study assessed safety, vaccine efficacy (VE) and immunogenicity against SARS-CoV-2 variants. The primary outcome was the non-inferiority of anti-spike protein receptor-binding domain (S-RBD IgG) antibodies, with a 97.5% confidence interval lower limit for the geometric mean concentration (GMC) ratio >0.67. Ad5-nCoV-IH showed lower immunogenicity than BNT-IM, with a GMC ratio of 0.22 and a seroconversion rate difference of -71.91%. Adverse drug reactions (ADRs) were less frequent with Ad5-nCoV-IH (39.26%) compared to BNT-IM (64.68%). No serious vaccine-related adverse events were reported. Both vaccines had comparable efficacy against COVID-19 variants. This study was funded by Tianjin Biomedical Science and Technology Major Project.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"9 1","pages":"209"},"PeriodicalIF":6.9,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11527888/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142558376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Regulatory review of benefits and risks of preventing infant RSV disease through maternal immunization. 对通过母体免疫接种预防婴儿 RSV 疾病的益处和风险进行监管审查。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2024-10-31 DOI: 10.1038/s41541-024-01002-y

Yugenia K Hong-Nguyen, Joseph Toerner, Lucia Lee, Maria C Allende, David C Kaslow

引用次数: 0

Immune correlates of protection as a game changer in tuberculosis vaccine development. 保护的免疫相关性是结核病疫苗研发中的一个转折点。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2024-10-30 DOI: 10.1038/s41541-024-01004-w

Jing Wang, Xiao-Yong Fan, Zhidong Hu

引用次数: 0

High protection and transmission-blocking immunity elicited by single-cycle SARS-CoV-2 vaccine in hamsters. 单周期 SARS-CoV-2 疫苗在仓鼠体内激发的高保护和传播阻断免疫力

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2024-10-30 DOI: 10.1038/s41541-024-00992-z

Martin Joseph Lett, Fabian Otte, David Hauser, Jacob Schön, Enja Tatjana Kipfer, Donata Hoffmann, Nico J Halwe, Angele Breithaupt, Lorenz Ulrich, Tobias Britzke, Jana Kochmann, Björn Corleis, Yuepeng Zhang, Lorena Urda, Vladimir Cmiljanovic, Christopher Lang, Martin Beer, Christian Mittelholzer, Thomas Klimkait

{"title":"High protection and transmission-blocking immunity elicited by single-cycle SARS-CoV-2 vaccine in hamsters.","authors":"Martin Joseph Lett, Fabian Otte, David Hauser, Jacob Schön, Enja Tatjana Kipfer, Donata Hoffmann, Nico J Halwe, Angele Breithaupt, Lorenz Ulrich, Tobias Britzke, Jana Kochmann, Björn Corleis, Yuepeng Zhang, Lorena Urda, Vladimir Cmiljanovic, Christopher Lang, Martin Beer, Christian Mittelholzer, Thomas Klimkait","doi":"10.1038/s41541-024-00992-z","DOIUrl":"10.1038/s41541-024-00992-z","url":null,"abstract":"Vaccines have played a central role in combating the COVID-19 pandemic, but newly emerging SARS-CoV-2 variants are increasingly evading first-generation vaccine protection. To address this challenge, we designed \"single-cycle infection SARS-CoV-2 viruses\" (SCVs) that lack essential viral genes, possess distinctive immune-modulatory features, and exhibit an excellent safety profile in the Syrian hamster model. Animals intranasally vaccinated with an Envelope-gene-deleted vaccine candidate were fully protected against an autologous challenge with the SARS-CoV-2 virus through systemic and mucosal humoral immune responses. Additionally, the deletion of immune-downregulating viral genes in the vaccine construct prevented challenge virus transmission to contact animals. Moreover, vaccinated animals displayed neither tissue inflammation nor lung damage. Consequently, SCVs hold promising potential to induce potent protection against COVID-19, surpassing the immunity conferred by natural infection, as demonstrated in human immune cells.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"9 1","pages":"206"},"PeriodicalIF":6.9,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11522273/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142546576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of adenoviral vector Ad19a encoding RSV-F as novel vaccine against respiratory syncytial virus. 评估将编码 RSV-F 的腺病毒载体 Ad19a 作为新型呼吸道合胞病毒疫苗的效果。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2024-10-29 DOI: 10.1038/s41541-024-01001-z

Jana Fuchs, Julian Hübner, Anna Schmidt, Pascal Irrgang, Clara Maier, Ana Vieira Antão, Friederike Oltmanns, Christian Thirion, Dennis Lapuente, Matthias Tenbusch

{"title":"Evaluation of adenoviral vector Ad19a encoding RSV-F as novel vaccine against respiratory syncytial virus.","authors":"Jana Fuchs, Julian Hübner, Anna Schmidt, Pascal Irrgang, Clara Maier, Ana Vieira Antão, Friederike Oltmanns, Christian Thirion, Dennis Lapuente, Matthias Tenbusch","doi":"10.1038/s41541-024-01001-z","DOIUrl":"10.1038/s41541-024-01001-z","url":null,"abstract":"Respiratory syncytial virus (RSV) is the leading cause of severe lower respiratory tract infections in infants and toddlers. Since natural infections do not induce persistent immunity, there is the need of vaccines providing long-term protection. Here, we evaluated a new adenoviral vector (rAd) vaccine based on the rare serotype rAd19a and compared the immunogenicity and efficacy to the highly immunogenic rAd5. Given as an intranasal boost in DNA primed mice, both vectors encoding the F protein provided efficient protection against a subsequent RSV infection. However, intramuscular immunization with rAd19a vectors provoked vaccine-enhanced disease after RSV infection compared to non-vaccinated animals. While mucosal IgA antibodies and tissue-resident memory T-cells in intranasally vaccinated mice rapidly control RSV replication, a strong anamnestic systemic T-cell response in absence of local immunity might be the reason for immune-mediated enhanced disease. Our study highlighted the potential benefits of developing effective mucosal against respiratory pathogens.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"9 1","pages":"205"},"PeriodicalIF":6.9,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11522487/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142546575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

mRNA COVID-19 vaccinations are not associated with RVO development 21 days and 12 weeks after vaccination. mRNA COVID-19 疫苗接种后 21 天和 12 周内与 RVO 的发生无关。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2024-10-28 DOI: 10.1038/s41541-024-00983-0

Jacqueline K Shaia, Priya Shukla, Lee Jampol, Rishi P Singh

引用次数: 0

Proteomic approach to identify host cell attachment proteins provides protective Pseudomonas aeruginosa vaccine antigen FtsZ. 用蛋白质组学方法鉴定宿主细胞附着蛋白，为铜绿假单胞菌疫苗抗原 FtsZ 提供保护。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2024-10-28 DOI: 10.1038/s41541-024-00994-x

Irene Jurado-Martín, Julen Tomás-Cortázar, Yueran Hou, Maite Sainz-Mejías, Margaritha M Mysior, Océane Sadonès, Johannes Huebner, Felipe Romero-Saavedra, Jeremy C Simpson, John A Baugh, Siobhán McClean

{"title":"Proteomic approach to identify host cell attachment proteins provides protective Pseudomonas aeruginosa vaccine antigen FtsZ.","authors":"Irene Jurado-Martín, Julen Tomás-Cortázar, Yueran Hou, Maite Sainz-Mejías, Margaritha M Mysior, Océane Sadonès, Johannes Huebner, Felipe Romero-Saavedra, Jeremy C Simpson, John A Baugh, Siobhán McClean","doi":"10.1038/s41541-024-00994-x","DOIUrl":"10.1038/s41541-024-00994-x","url":null,"abstract":"Pseudomonas aeruginosa is an opportunistic Gram-negative pathogen that causes severe nosocomial infections in susceptible individuals due to the emergence of multidrug-resistant strains. There are no approved vaccines against P. aeruginosa infections nor candidates in active clinical development, highlighting the need for novel candidates and strategies. Using a cell-blot proteomic approach, we reproducibly identified 49 proteins involved in interactions with human lung epithelial cells across four P. aeruginosa strains. Among these were cell division protein FtsZ and outer membrane protein OpmH. Escherichia coli BL21 cells overexpressing recombinant FtsZ or rOpmH showed a 66- and 15-fold increased ability to attach to 16HBE14o- cells, further supporting their involvement in host cell attachment. Both antigens led to proliferation of NK and CD8+ cytotoxic T cells, significant increases in the production of IFN-γ, IL-17A, TNF and IL-4 in immunised mice and elicited strong antigen-specific serological IgG1 and IgG2c responses. Immunisation with FtsZ significantly reduced bacterial burden in the lungs by 1.9-log CFU and dissemination to spleen by 1.8-log CFU. The protective antigen candidate, FtsZ, would not have been identified by traditional approaches relying on either virulence mechanisms or sequence-based predictions, opening new avenues in the development of an anti-P. aeruginosa vaccine.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"9 1","pages":"204"},"PeriodicalIF":6.9,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11519640/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142522546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reply to: mRNA COVID-19 vaccinations are not associated with RVO development 21 days and 12 weeks after vaccination. 回复：接种 mRNA COVID-19 疫苗与接种后 21 天和 12 周的 RVO 发展无关。

IF 6.9 1区医学

NPJ Vaccines Pub Date : 2024-10-28 DOI: 10.1038/s41541-024-00984-z

Jing-Xing Li, Yu-Hsun Wang, Henry Bair, Shu-Bai Hsu, Connie Chen, James Cheng-Chung Wei, Chun-Ju Lin

引用次数: 0